Authors: Chacra, A. R.¹; Tan, G. H.²; Apanovitch, A.³; Ravichandran, S.³; List, J.³; Chen, R.³

Source: International Journal of Clinical Practice, Volume 63, Number 9, September 2009 , pp. 1395-1406(12)

Publisher: Wiley-Blackwell

Abstract:

Summary Aims: 

Assess the efficacy and safety of saxagliptin added to a submaximal sulphonylurea dose vs. uptitration of sulphonylurea monotherapy in patients with type 2 diabetes and inadequate glycaemic control with sulphonylurea monotherapy. Methods and patients: 

A total of 768 patients (18-77 years; HbA_1c screening ≥ 7.5 to ≤ 10.0%) were randomised and treated with saxagliptin 2.5 or 5 mg in combination with glyburide 7.5 mg vs. glyburide 10 mg for 24 weeks. Blinded uptitration glyburide was allowed in the glyburide-only arm to a maximum total daily dose of 15 mg. Efficacy analyses were performed using ANCOVA and last-observation-carried-forward methodology. Results: 

At week 24, 92% of glyburide-only patients were uptitrated to a total glyburide dose of 15 mg/day. Saxagliptin 2.5 and 5 mg provided statistically significant adjusted mean decreases from baseline to week 24 vs. uptitrated glyburide, respectively, in HbA_1c (−0.54%, −0.64% vs. +0.08%; both p < 0.0001) and fasting plasma glucose (−7, −10 vs. +1 mg/dl; p = 0.0218 and p = 0.002). The proportion of patients achieving an HbA_1c < 7% was greater for saxagliptin 2.5 and 5 mg vs. uptitrated glyburide (22.4% and 22.8% vs. 9.1%; both p < 0.0001). Postprandial glucose area under the curve was reduced for saxagliptin 2.5 and 5 mg vs. uptitrated glyburide (−4296 and −5000 vs. +1196 mg·min/dl; both p < 0.0001). Adverse event occurrence was similar across all groups. Reported hypoglycaemic events were not statistically significantly different for saxagliptin 2.5 (13.3%) and 5 mg (14.6%) vs. uptitrated glyburide (10.1%). Conclusion: 

Saxagliptin added to submaximal glyburide therapy led to statistically significant improvements vs. uptitration of glyburide alone across key glycaemic parameters and was generally well tolerated.

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1742-1241.2009.02143.x

Affiliations: 1: Diabetes Center, Federal University of São Paulo, São Paulo, Brazil 2: Cebu Doctors' University College of Medicine, Cebu Doctors' University Hospital, Cebu City, Philippines 3: Bristol-Myers Squibb, Princeton, NJ, USA

Publication date: 2009-09-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine (General)
• By this author: Chacra, A. R. ;  Tan, G. H. ;  Apanovitch, A. ;  Ravichandran, S. ;  List, J. ;  Chen, R.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers